Gao BaoXi, Qu Yusheng, Sutherland Weston, Chui Ray W, Hoagland Kim, Vargas Hugo M
Integrated Discovery and Safety Pharmacology, Amgen. Inc., Thousand Oaks, CA 91320, United States.
Integrated Discovery and Safety Pharmacology, Amgen. Inc., Thousand Oaks, CA 91320, United States.
J Pharmacol Toxicol Methods. 2018 Sep-Oct;93:98-107. doi: 10.1016/j.vascn.2018.06.001. Epub 2018 Jun 14.
Contractility measurements using primary isolated cardiac myocytes (CM) have commonly been used in understanding the physiology and pharmacology of cellular mechanics. In the majority of studies, CM from healthy animals were used, and fewer studies were performed with CM from diseased hearts. To better understand the translational value of contractility on the cellular level of a diseased animal model, myocytes were isolated from left ventricles of a tachypacing-induced heart failure (HF) canine model, and their contractility was measured by recording sarcomere shortening using an image-based IonOptix video system. A side-by-side comparison study was performed in myocytes isolated from 13 normal and 5 tachypacing-induced HF canines by evaluating both basal contractility and pharmacological responses to inotropic agents with different mechanisms, including dobutamine, isoproterenol, milrinone, levosimendan, pimobendan, diltiazem, and flecainide. Myocytes isolated from HF canines exhibited compromised contractility at the sarcomere level in comparison to normal myocytes, specifically, HF myocytes have smaller sarcomere contraction amplitude, longer resting sarcomere length, slower velocity of contraction and relaxation. In addition, they have altered pharmacological responses compared to that of normal canines, with much less potent effects observed in the application of classic inotropic agents, such as isoproterenol, dobutamine, and milrinone. These results indicate that myocytes isolated from tachy-paced HF canines have altered physiological and pharmacological properties, which could be utilized for understanding pathophysiology and developing pharmacological interventions for HF.
使用原代分离心肌细胞(CM)进行收缩性测量,已普遍用于理解细胞力学的生理学和药理学。在大多数研究中,使用的是来自健康动物的CM,而对来自患病心脏的CM进行的研究较少。为了更好地理解收缩性在患病动物模型细胞水平上的转化价值,从快速起搏诱导的心力衰竭(HF)犬模型的左心室中分离出心肌细胞,并使用基于图像的IonOptix视频系统记录肌节缩短来测量其收缩性。通过评估基础收缩性以及对具有不同作用机制的正性肌力药物(包括多巴酚丁胺、异丙肾上腺素、米力农、左西孟旦、匹莫苯丹、地尔硫卓和氟卡尼)的药理反应,对从13只正常犬和5只快速起搏诱导的HF犬分离出的心肌细胞进行了平行比较研究。与正常心肌细胞相比,从HF犬分离出的心肌细胞在肌节水平上表现出收缩性受损,具体而言,HF心肌细胞的肌节收缩幅度较小、静息肌节长度较长、收缩和舒张速度较慢。此外,与正常犬相比,它们的药理反应发生了改变,在应用经典正性肌力药物(如异丙肾上腺素、多巴酚丁胺和米力农)时观察到的效果要弱得多。这些结果表明,从快速起搏的HF犬分离出的心肌细胞具有改变的生理和药理特性,这可用于理解病理生理学并开发针对HF的药理干预措施。